- Home
- NA vs NRXP Comparison
NA vs NRXP Comparison
Compare NA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | NRXP |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0M | 62.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | NA | NRXP |
|---|---|---|
| Price | $3.21 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 39.9K | ★ 1.8M |
| Earning Date | 03-24-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,369,693.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $1.58 |
| 52 Week High | $31.48 | $3.84 |
Technical Indicators
Market Signals| Indicator | NA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 43.49 |
| Support Level | $2.81 | $1.65 |
| Resistance Level | $3.84 | $2.17 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 30.84 | 43.03 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.